[{"id":"94f67e06-7b3a-4c47-96a6-5ce0261a41a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05532696","created_at":"2022-09-08T13:55:08.527Z","updated_at":"2024-07-02T16:35:24.614Z","phase":"Phase 1/2","brief_title":"Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","source_id_and_acronym":"NCT05532696","lead_sponsor":"Anbogen Therapeutics, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gozanertinib (ABT-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 09/27/2022","start_date":" 09/27/2022","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-01-04"}]